Skip to main content
Log in

circTAB2 inhibits lung cancer proliferation, migration and invasion by sponging miR-3142 to upregulate GLIS2

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Circular RNAs (circRNAs) are a specialized circular structure, are deregulated in cancers and play essential roles in biological processes involved in tumor progression. However, the mechanism by which circRNAs affect lung tumorigenesis and progression remains largely unexplored. To investigate the role of circRNA in lung cancer, circRNA expression profile was screened by bioinformatics analysis. The levels of circTAB2, miR-3142, and GLIS family zinc finger 2 (GLIS2) were measured by quantitate real-time (qRT-PCR) or western blot. Cell proliferation, apoptosis, migration and invasion were detected by EdU, flow cytometry, and transwell assays, respectively. Bioinformatics, western blot, RIP, pull down, dual luciferase reporter and rescue experiments were used to verify the direct relationship between miR-3142 and circTAB2 or GLIS2. The xenograft assays were used to assess the role of circTAB2 in vivo.CircTAB2 exhibited low expression in cancer tissues. Gain and loss-of-function assays indicated that circTAB2 could inhibit cell proliferation, migration and invasion. Functional studies revealed that circTAB2 acted as a miRNA sponge, directly interacted with miR-3142 and consequently regulated GLIS2 /AKT. Taken together, circTAB2 serves as an inhibitory role in lung cancer through a novel circTAB2 /miR-3142 /GLIS2 /AKT pathway and could be exploited a novel marker in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data Availability

The data and study materials that support the findings of this study will be available to other researchers from the corresponding authors on reasonable request.

References

  1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249

    Article  PubMed  Google Scholar 

  2. Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446–454

    Article  CAS  PubMed  Google Scholar 

  3. Li J, Kwok HF (2020) Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers (Basel). https://doi.org/10.3390/cancers12061587

    Article  PubMed  PubMed Central  Google Scholar 

  4. Jeck WR, Sorrentino JA, Wang K et al (2013) Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19:141–157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Vo JN, Cieslik M, Zhang Y et al (2019) The Landscape of Circular RNA in Cancer. Cell 176(869–881):e813

    Google Scholar 

  6. Shang Q, Yang Z, Jia R et al (2019) The novel roles of circRNAs in human cancer. Mol Cancer 18:6

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hua J, Wang X, Ma L et al (2022) CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. Mol Cancer 21:123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zhang LX, Gao J, Long X et al (2022) The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Mol Cancer 21:110

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wu D, Chen T, Zhao X et al (2022) HIF1alpha-SP1 interaction disrupts the circ-0001875/miR-31-5p/SP1 regulatory loop under a hypoxic microenvironment and promotes non-small cell lung cancer progression. J Exp Clin Cancer Res 41:156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen D, Zhou H, Cai Z et al (2022) CircSCAP interacts with SF3A3 to inhibit the malignance of non-small cell lung cancer by activating p53 signaling. J Exp Clin Cancer Res 41:120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang T, Wu DM, Luo PW et al (2022) CircNEIL3 mediates pyroptosis to influence lung adenocarcinoma radiotherapy by upregulating PIF1 through miR-1184 inhibition. Cell Death Dis 13:167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Goodall GJ, Wickramasinghe VO (2021) RNA in cancer. Nat Rev Cancer 21:22–36

    Article  CAS  PubMed  Google Scholar 

  13. Luo YH, Yang YP, Chien CS et al (2020) Plasma Level of Circular RNA hsa_circ_0000190 correlates with tumor progression and poor treatment response in advanced lung cancers. Cancers (Basel) 12:1740

    Article  CAS  PubMed  Google Scholar 

  14. Glazar P, Papavasileiou P, Rajewsky N (2014) circBase: a database for circular RNAs. RNA 20:1666–1670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kent WJ, Sugnet CW, Furey TS et al (2002) The human genome browser at UCSC. Genome Res 12:996–1006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Suzuki H, Zuo Y, Wang J et al (2006) Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res 34:e63

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388

    Article  CAS  PubMed  Google Scholar 

  18. Hauptmann J, Meister G (2013) Argonaute regulation: two roads to the same destination. Dev Cell 25:553–554

    Article  CAS  PubMed  Google Scholar 

  19. Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48:D127–D131

    Article  CAS  PubMed  Google Scholar 

  20. Dudekula DB, Panda AC, Grammatikakis I et al (2016) CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol 13:34–42

    Article  PubMed  Google Scholar 

  21. Feng J, Chen W, Dong X et al (2022) CSCD2: an integrated interactional database of cancer-specific circular RNAs. Nucleic Acids Res 50:D1179–D1183

    Article  CAS  PubMed  Google Scholar 

  22. Sticht C, De La Torre C, Parveen A et al (2018) miRWalk: An online resource for prediction of microRNA binding sites. PLoS ONE 13:e0206239

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20

    Article  CAS  PubMed  Google Scholar 

  24. Szklarczyk D, Gable AL, Nastou KC et al (2021) The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 49:D605–D612

    Article  CAS  PubMed  Google Scholar 

  25. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

    Article  CAS  PubMed  Google Scholar 

  26. Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33

    Article  PubMed  Google Scholar 

  27. Salmena L, Poliseno L, Tay Y et al (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146:353–358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Luo Q, Wang H, Li J (2019) Serum miR-3142 could be used as a potential biomarker to screen cervical cancer patients from healthy controls. Clin Lab. https://doi.org/10.7754/Clin.Lab.2018.180925

    Article  PubMed  Google Scholar 

  29. Zhang F, Jetten AM (2001) Genomic structure of the gene encoding the human GLI-related, Krüppel-like zinc finger protein GLIS2. Gene 280:49–57

    Article  CAS  PubMed  Google Scholar 

  30. Lichti-Kaiser K, ZeRuth G, Kang HS et al (2012) Gli-similar proteins: their mechanisms of action, physiological functions, and roles in disease. Vitam Horm 88:141–171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wilson MM, Callens C, Le Gallo M et al (2021) An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Sci Adv. https://doi.org/10.1126/sciadv.abf6063

    Article  PubMed  PubMed Central  Google Scholar 

  32. Guerra E, Trerotola M, Aloisi AL et al (2013) The Trop-2 signalling network in cancer growth. Oncogene 32:1594–1600

    Article  CAS  PubMed  Google Scholar 

  33. Kim YS, Kang HS, Jetten AM (2007) The Krüppel-like zinc finger protein Glis2 functions as a negative modulator of the Wnt/beta-catenin signaling pathway. FEBS Lett 581:858–864

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. He L, Li Q, Du C et al (2022) Glis2 inhibits the epithelial-mesenchymal transition and apoptosis of renal tubule cells by regulating the beta-catenin signalling pathway in diabetic kidney disease. Biochem Biophys Res Commun 607:73–80

    Article  CAS  PubMed  Google Scholar 

  35. Sun H, Gu J, Li Z et al (2019) Low expression of GLIS2 gene might associate with radiosensitivity of gastric cancer. J Oncol 2019:2934925

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yao J, Lei PJ, Li QL et al (2020) GLIS2 promotes colorectal cancer through repressing enhancer activation. Oncogenesis 9:57

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by National Key Research and Development Program (2022YFC3600100, 2019YFA0903802) to YW, high-level talents of Youjiang Medical College for Nationalities (YY2021SK02) to LJ.

Author information

Authors and Affiliations

Authors

Contributions

Youliang Wang, Lihe Jiang and Yanli Lin designed and supervised the manuscript. Weiling Man, Yumeng Cui, Yanghua Li, Jie Jin, Yang Jin, Xiaojie Wu, Rongbin Zhong, Xiang Li and He Yao collected the data and conducted the statistical analyses. Weiling Man wrote the manuscript. Jie Li collected the clinical sample. All authors read and approved the manuscript.

Corresponding authors

Correspondence to Yanli Lin, Lihe Jiang or Youliang Wang.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Ethical approval

Studies using human tissues and plasma samples were approved by the Ethics Committee of Chinese PLA General Hospital were performed in accordance with the principles of Declaration of Helsinki. The animal study was approved by the Animal Ethic Review Committees of Beijing Institute of Biotechnology. All animal experiments were strictly implemented in compliance with the NIH Guide for the Care and Use of Laboratory Animals.

Consent to participate and consent to publish

The patients provided their written informed consent to participate in this study. We have obtained consent to publish this paper from all the participants of this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Man, W., Cui, Y., Li, J. et al. circTAB2 inhibits lung cancer proliferation, migration and invasion by sponging miR-3142 to upregulate GLIS2. Apoptosis 28, 471–484 (2023). https://doi.org/10.1007/s10495-022-01805-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-022-01805-1

Keywords

Navigation